SV301

SV301 is a preclinical-stage personalized therapeutic cancer vaccine being developed by Sysvax (Beijing Sysvax Biotechnology). It is designed to target tumor-specific neoantigens identified through genomic sequencing of a patient's tumor. By presenting these unique antigens to the immune system, the vaccine aims to stimulate a robust, patient-specific T-cell response against multiple tumor types, including cervical cancer. This personalized approach is intended to overcome the limitations of universal vaccines by addressing the high degree of mutational heterogeneity between individual patients and their tumors. SV301 is part of Sysvax's broader pipeline of therapeutic vaccines utilizing their proprietary antigen discovery and delivery platforms.